A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs PRX 002 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Neotope Biosciences; Prothena
  • Most Recent Events

    • 13 Dec 2016 Results published in the Prothena Corporation Media Release.
    • 13 Dec 2016 According to Prothena Corporation media release, clinical results were published in Movement Disorders Journal.
    • 25 Nov 2016 Results published in the Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top